JP2017160212A5 - - Google Patents

Download PDF

Info

Publication number
JP2017160212A5
JP2017160212A5 JP2017074526A JP2017074526A JP2017160212A5 JP 2017160212 A5 JP2017160212 A5 JP 2017160212A5 JP 2017074526 A JP2017074526 A JP 2017074526A JP 2017074526 A JP2017074526 A JP 2017074526A JP 2017160212 A5 JP2017160212 A5 JP 2017160212A5
Authority
JP
Japan
Prior art keywords
insulin
per day
dapagliflozin
dosage
rosiglitazone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017074526A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017160212A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017160212A publication Critical patent/JP2017160212A/ja
Publication of JP2017160212A5 publication Critical patent/JP2017160212A5/ja
Pending legal-status Critical Current

Links

JP2017074526A 2009-05-27 2017-04-04 別の抗糖尿病薬を用いた先の治療に抵抗性を有する2型糖尿病患者をsglt2阻害剤およびその組成物を用いて治療する方法 Pending JP2017160212A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18144209P 2009-05-27 2009-05-27
US61/181,442 2009-05-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015241499A Division JP2016104753A (ja) 2009-05-27 2015-12-10 別の抗糖尿病薬を用いた先の治療に抵抗性を有する2型糖尿病患者をsglt2阻害剤およびその組成物を用いて治療する方法

Publications (2)

Publication Number Publication Date
JP2017160212A JP2017160212A (ja) 2017-09-14
JP2017160212A5 true JP2017160212A5 (OSRAM) 2018-03-01

Family

ID=42334303

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012513184A Withdrawn JP2012528170A (ja) 2009-05-27 2010-05-26 別の抗糖尿病薬を用いた先の治療に抵抗性を有する2型糖尿病患者をsglt2阻害剤およびその組成物を用いて治療する方法
JP2015241499A Pending JP2016104753A (ja) 2009-05-27 2015-12-10 別の抗糖尿病薬を用いた先の治療に抵抗性を有する2型糖尿病患者をsglt2阻害剤およびその組成物を用いて治療する方法
JP2017074526A Pending JP2017160212A (ja) 2009-05-27 2017-04-04 別の抗糖尿病薬を用いた先の治療に抵抗性を有する2型糖尿病患者をsglt2阻害剤およびその組成物を用いて治療する方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2012513184A Withdrawn JP2012528170A (ja) 2009-05-27 2010-05-26 別の抗糖尿病薬を用いた先の治療に抵抗性を有する2型糖尿病患者をsglt2阻害剤およびその組成物を用いて治療する方法
JP2015241499A Pending JP2016104753A (ja) 2009-05-27 2015-12-10 別の抗糖尿病薬を用いた先の治療に抵抗性を有する2型糖尿病患者をsglt2阻害剤およびその組成物を用いて治療する方法

Country Status (5)

Country Link
US (1) US8685934B2 (OSRAM)
EP (1) EP2435033A1 (OSRAM)
JP (3) JP2012528170A (OSRAM)
CN (2) CN102639125A (OSRAM)
WO (1) WO2010138535A1 (OSRAM)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
US20110046076A1 (en) 2009-02-13 2011-02-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ES2596202T3 (es) * 2009-09-30 2017-01-05 Boehringer Ingelheim International Gmbh Método para la preparación de una forma cristalina de 1-cloro-4-(ß-D-glucopiranos-1-il)-2-[4-((S)-tetrahidrofuran-3-iloxi)-bencil]-benceno
BR112012007085B8 (pt) 2009-09-30 2021-05-25 Boehringer Ingelheim Int processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila
UY32919A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
BR112012011726A2 (pt) 2009-11-13 2020-05-19 Bristol-Myers Squibb Company comprimidos de duas camadas, seu uso, e suas combinações farmacêuticas
JP5784623B2 (ja) 2009-11-13 2015-09-24 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag 速放性錠剤製剤
JP2013523681A (ja) * 2010-03-30 2013-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Sglt2インヒビター及びppar−ガンマアゴニストを含む医薬組成物並びにその使用
US20120283169A1 (en) * 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
WO2013095316A1 (en) * 2011-12-19 2013-06-27 Mahmut Bilgic Synergic combination comprising anti-diabetic agent
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN104780942A (zh) * 2012-08-30 2015-07-15 大正制药株式会社 Sglt2抑制剂和抗高血压药的组合
ES2740299T3 (es) 2013-03-14 2020-02-05 Msd Int Gmbh Métodos para preparar inhibidores de SGLT2
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303098A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
DK2986304T3 (da) 2013-04-18 2022-04-04 Boehringer Ingelheim Int Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf.
EP2991999B1 (en) 2013-04-29 2019-05-08 Mapi Pharma Limited Dapagliflozin lactose co-crystal
CN104496952B (zh) * 2014-11-28 2017-04-19 深圳翰宇药业股份有限公司 一种达格列净的合成方法
SMT202400104T1 (it) * 2015-04-07 2024-05-14 Intercept Pharmaceuticals Inc Composizioni farmaceutiche per politerapia
US10464933B2 (en) * 2016-02-03 2019-11-05 Dr. Reddy's Laboratories Limited Solid state forms of dasatinib and processes for their preparation
CN108430467B (zh) * 2016-05-20 2021-06-22 晟德大药厂股份有限公司 (r)-(+)-维拉帕米用于治疗高血糖的用途及其药学组合物
BR112019008384A2 (pt) 2016-11-10 2019-07-09 Boehringer Ingelheim Int composição farmacêutica, processos para tratamento e seus usos
WO2018167589A1 (en) 2017-03-16 2018-09-20 Inventia Healthcare Private Limited Pharmaceutical composition comprising dapagliflozin
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
ES3035734T3 (en) * 2017-11-30 2025-09-08 Idorsia Pharmaceuticals Ltd Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
US10639292B2 (en) 2018-04-20 2020-05-05 Center Laboratories, Inc. Method of treating hyperglycemia
SMT202500107T1 (it) * 2018-05-31 2025-05-12 Hua Medicine Shanghai Ltd Combinazione, composizione e preparazione di combinazione farmaceutiche comprendenti attivatore di glucochinasi e inibitore di sglt-2, e relativi metodo di preparazione e uso
US11495339B2 (en) * 2018-06-14 2022-11-08 Astrazeneca Uk Limited Methods for lowering blood sugar with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
EP4082532A4 (en) * 2019-12-24 2024-03-13 Hanmi Pharm. Co., Ltd. COMPLEX FORMULATION COMPRISING SITAGLIPTIN AND DAPAGLIFLOZIN, AND PREPARATION METHOD THEREFOR
MX2022012557A (es) * 2020-04-10 2023-01-19 Chinook Therapeutics Inc Metodos de tratamiento de la enfermedad renal diabetica.
EP4138826A1 (en) 2020-04-22 2023-03-01 Bayer Aktiengesellschaft Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
KR102838283B1 (ko) * 2020-07-10 2025-07-25 한미약품 주식회사 시타글립틴 및 다파글리플로진을 포함하는 복합제제 및 그 제조방법
US12409186B2 (en) 2020-07-27 2025-09-09 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
EP4236957A4 (en) * 2020-10-30 2024-08-07 Resverlogix Corp. METHODS OF LOWERING HBA1C LEVELS USING A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A SODIUM-DEPENDENT GLUCOSE TRANSPORT-2 INHIBITOR
CN114671839B (zh) * 2020-12-25 2024-01-09 天地恒一制药股份有限公司 达格列净的固体形式复合物及其制备方法与应用
US20250108065A1 (en) * 2022-01-26 2025-04-03 Astrazeneca Ab Methods of treating prediabetes or reducing the risk of developing type 2 diabetes with dapagliflozin
EP4493272A1 (en) * 2022-03-14 2025-01-22 University Of Virginia Patent Foundation Combination sodium-glucose cotransporter inhibitor (sglti)- insulin therapy for glycemic control in type 1 diabetes
EP4385502A1 (en) * 2022-12-15 2024-06-19 Sanovel Ilac Sanayi Ve Ticaret A.S. A pharmaceutical formulation comprising metformin, pioglitazone and a sglt-2 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6936590B2 (en) * 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
IL149851A0 (en) 2002-05-26 2002-11-10 Yeda Res & Dev Resistin binding proteins, their preparation and use
TW200904405A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
WO2010045656A2 (en) * 2008-10-17 2010-04-22 Nectid, Inc. Novel sglt2 inhibitor dosage forms

Similar Documents

Publication Publication Date Title
JP2017160212A5 (OSRAM)
JP2011521940A5 (OSRAM)
JP2013522194A5 (OSRAM)
JP2009542702A5 (OSRAM)
JP2016501841A5 (OSRAM)
JP2009542699A5 (OSRAM)
AU2016205138A1 (en) ACC inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
JP2018513188A5 (OSRAM)
JP2016528301A5 (OSRAM)
JP2015187125A5 (OSRAM)
BRPI0519471A2 (pt) formulaÇço complexa de liberaÇço controlada para administraÇço oral de medicamentos para diabÉticos e mÉtodo para o seu preparo
KR20210005843A (ko) Glp1r 작용제의 치료적 용도
JP2013532658A5 (OSRAM)
JP2008520544A5 (ja) 癌関連疲労の治療または予防のための医薬の製造への使用方法
FI4124339T3 (fi) Lääkkeenantojärjestelmiä ja -menetelmiä virtsarakon syövän hoitoon gemsitabiinilla
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
JP2018138596A5 (OSRAM)
JP2019520344A5 (OSRAM)
JPWO2021045159A5 (OSRAM)
JP2010511039A5 (OSRAM)
JP2020536121A5 (OSRAM)
JP2010500284A5 (OSRAM)
MX390101B (es) Tratamiento medico que comprende administracion enteral de edaravona
JP2011500589A5 (OSRAM)
RU2020120156A (ru) Лечение приливов и потери костной ткани, вызванных андрогенной депривационной терапией с применением цис-кломифена